The pace of initial public offerings in the US predictably slowed during the summer, although whether the slowdown was caused by financial market conditions or vacation schedules remains to be seen. Even so, three drug developers spent their summers filing paperwork with the US Securities and Exchange Commission (SEC) in support of future IPOs, each of which could be the first $100m-plus first-time offerings since mid-July.
Finance Watch: Zenas, Bicara, MBX Aim To Raise $100m Or More In Future IPOs
Redalpine’s $200m VC Fund Backs Tech And Biotech
Fifteen biopharma firms have launched IPOs in the US this year, but three more have joined the queue. Also, Galderma sold CHF500m ($590.7m) in bonds to pay down debt, Noetik raised a $40m series A round and ImCheck collected €20.18m ($22.4m) from the French government.

More from Financing
More from Business
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.